Exchange: NYSE·Updated 04:05 AM EDT
GMED logo

GMEDGlobus Medical Inc

$80.40
$0.18
(0.22%)
Pre-Market
Prev Close $80.58
EarningsAug 6
Mkt Cap$10.62B
Vol6.00
News
all
press releases
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm PR Newswire NEW YORK, July 28, 2026 NEW YORK, July 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...
PR Newswire
More News
Reasons to Retain Globus Medical Stock in Your Portfolio for Now
GMED is gaining share in musculoskeletal solutions with strong implant and trauma growth, backed by a debt-free balance sheet despite cost and FX pressures.
Zacks
GMED Stock Surges 43.6% in a Year: What's Driving the Rally?
Globus Medical's 43.6% one-year rally is fueled by strong growth across both business segments, rising technology adoption and a debt-free balance sheet.
Zacks
Reasons to Retain Alignment Healthcare Stock in Your Portfolio for Now
ALHC's AI and automation are boosting margins and efficiency, but CMS risk model changes and revenue timing cloud near-term earnings visibility.
Zacks
Here's Why Globus Medical (GMED) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Reasons to Retain Abbott Stock in Your Portfolio for Now
ABT is banking on emerging-market pharmaceutical growth and innovation in Nutrition, but macro pressures and currency swings remain key challenges.
Zacks
IART Stock Surges 52.1% in a Year: What's Driving the Rally?
Integra LifeSciences has climbed 52.1% in a year as growth across both segments, improved execution and transformation efforts continue to boost results.
Zacks
Can ISRG Defend Its Leadership as Global Competition Intensifies?
ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price.
Zacks
ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?
ISRG is set to report Q2 results on July 16, with sales and EPS expected to rise, while investors weigh margin pressure against strong adoption of da Vinci 5.
Zacks
Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?
ZBH is banking on knee growth, robotics and restructuring to drive results, but can macro pressures and competition limit the upside?
Zacks
<
1
2
>

Advertisement|Remove ads.